BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer

Trial Profile

BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Fluorouracil; Mitomycin
  • Indications Anal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 Status changed from active, no longer recruiting to discontinued.
    • 25 Jan 2018 Results were presented in an Advaxis media release.
    • 25 Jan 2018 According to an Advaxis media release, data from this investigator-initiated study were published in the International Journal of Radiation Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top